Pharmacy Benefit Managers (PBMs): The Hidden Middlemen Shaping Your Prescription Drug Costs
When you fill a prescription, you might assume the price you pay is set by the drug manufacturer or negotiated directly between your insurer and the pharmacy. But in reality, a little-known industry—pharmacy benefit managers (PBMs)—often dictates what you pay, which pharmacies you can use, and even whether your medication gets approved. These middlemen, which control over 80% of the U.S. Prescription drug market, have faced growing scrutiny for their role in driving up drug costs, reducing transparency, and squeezing independent pharmacies.
With federal and state policymakers pushing for reform, and a recent wave of legislative actions targeting PBM practices, understanding their influence is more critical than ever. Here’s what you need to know about how PBMs operate—and why their power is under the microscope.
What Are Pharmacy Benefit Managers (PBMs)?
PBMs act as intermediaries between drug manufacturers, pharmacies, insurers, and patients. Their core functions include:
- Negotiating rebates and discounts with drugmakers, often keeping a portion for themselves.
- Designing drug formularies—lists of covered medications—that influence which drugs patients can access.
- Processing claims and determining reimbursement rates for pharmacies.
- Implementing utilization management tools like prior authorizations and step therapy, which can delay or deny patient access to medications.
- Steering patients to preferred pharmacies, often owned by or affiliated with the PBM or insurer.
Founded in the 1960s to help control rising drug costs, PBMs have since consolidated into a dominant oligopoly, with just three companies—CVS Caremark, Express Scripts (now part of Cigna), and OptumRx (UnitedHealth Group)—controlling the majority of the market. This concentration has raised concerns about reduced competition, opaque pricing, and conflicts of interest.
How PBMs Influence Drug Pricing—and What You Pay
PBMs wield significant power over prescription drug costs through several mechanisms:
1. Rebate Negotiations: The “Double Discount” Game
PBMs negotiate rebates from drug manufacturers—often 20% to 50% of a drug’s list price. However, studies show that only a fraction of these rebates are passed through to consumers, with the rest retained by PBMs, insurers, or employers. This practice, known as the “rebate cliff,” can actually increase out-of-pocket costs for patients when they switch to a lower-cost drug not covered by the rebate agreement.
2. Formulary Design: Controlling What You Can Access
PBMs determine which drugs make it onto insurers’ formularies—and at what tier (e.g., preferred, non-preferred). Drugs not on the formulary may require costly prior authorizations or step therapy, where patients must try (and fail) cheaper alternatives first. A 2025 study in JAMA Health Forum found that PBM-owned pharmacies were more likely to steer patients to in-network locations, often at lower reimbursement rates than independent pharmacies.
3. Pharmacy Reimbursement: The “Spread Pricing” Scheme
PBMs often use spread pricing, where they pay pharmacies less than the amount charged to insurers. For example, a PBM might charge an insurer $100 for a drug but reimburse the pharmacy only $60, keeping the difference. This practice has led to closures of independent pharmacies, which cannot compete with the deep pockets of corporate chains favored by PBMs.
Why PBMs Are Controversial: Key Criticisms
⚖️ Lack of Transparency
PBMs operate behind closed doors, making it tricky for patients, pharmacies, and even some insurers to understand how rebates, fees, and reimbursement rates are calculated. A 2026 KFF report highlights how this opacity contributes to higher overall drug spending without clear benefits to consumers.
💰 Higher Costs for Consumers
Despite their role in negotiating discounts, PBMs have been linked to rising drug prices. The American Medical Association (AMA) argues that their business model incentivizes higher list prices, as manufacturers raise prices to secure larger rebates—even if the net cost to patients doesn’t decrease.
🏥 Harm to Independent Pharmacies
PBMs often favor large chain pharmacies or those they own, leaving independent pharmacies with unsustainable reimbursement rates. A 2025 analysis of Medicare Part D data found that patients were more likely to be directed to PBM-affiliated pharmacies, which may offer lower-quality care or fewer services than local, community pharmacies.
🤝 Conflicts of Interest
Many PBMs are owned by or vertically integrated with health insurers (e.g., UnitedHealth’s OptumRx, CVS’s Caremark). This creates conflicts when PBMs negotiate with the same insurers they report to, potentially prioritizing profits over patient access or cost savings.
Pushing for Reform: What’s Changing in 2026?
The pressure on PBMs has never been greater. Recent federal and state actions aim to increase transparency, reduce conflicts of interest, and ensure patients benefit from rebates. Key developments include:
- Inflation Reduction Act (IRA) Provisions (2022): While primarily focused on Medicare drug price negotiation, the IRA also requires PBMs to disclose more about their pricing practices and rebate pass-through policies.
- State-Level Legislation: Over a dozen states have passed or proposed laws to cap PBM fees, mandate rebate transparency, or prohibit anti-competitive practices. For example, Florida and Texas have introduced bills to limit PBM ownership of pharmacies.
- Federal Oversight: The Centers for Medicare & Medicaid Services (CMS) is reviewing PBM contracts for Medicare Part D and Medicaid, with plans to publish more data on rebates and pharmacy reimbursement rates.
- Industry Pushback: The Pharmaceutical Care Management Association (PCMA), the PBM industry trade group, has lobbied against reform, arguing that PBMs already drive down costs. However, critics counter that their savings are often hidden or misdirected.
Will these reforms make a difference? Early signs suggest they could force PBMs to become more transparent—but whether they’ll lead to lower costs for patients remains to be seen.
FAQ: Pharmacy Benefit Managers Explained
Q: Do PBMs actually lower drug prices?
A: PBMs negotiate rebates that can reduce the net cost of drugs for insurers and employers. However, these savings are often not passed through to consumers, and the rebate system can perpetuate higher list prices rather than lower them.
Q: How do PBMs affect my insurance coverage?
A: PBMs determine which drugs are covered by your plan (the formulary), whether you need prior authorization, and which pharmacies are in-network. If your preferred pharmacy isn’t contracted with your PBM, you may pay more out of pocket.
Q: Can I avoid PBM fees?
A: Not directly—but you can ask your employer or insurer about their PBM contracts and whether rebates are being passed through to lower premiums. Some states are also exploring transparency laws that could give patients more information.
Q: Are PBMs illegal?
A: No, but their practices are increasingly scrutinized for anti-competitive behavior, lack of transparency, and conflicts of interest. Recent legislative efforts aim to regulate these issues without banning PBMs outright.
Key Takeaways: What Patients and Policymakers Need to Know
- PBMs are powerful intermediaries that influence drug costs, formulary access, and pharmacy choices—but their operations are often opaque.
- Rebates don’t always mean lower costs for patients; PBMs may keep savings while raising list prices.
- Independent pharmacies are at risk due to PBM steering and lower reimbursement rates.
- Reform is coming, with federal and state laws pushing for more transparency and fairer practices.
- Patients can take action by advocating for transparency, choosing plans with clear formulary policies, and supporting independent pharmacies.
The Future of PBMs: More Scrutiny, More Questions
Pharmacy benefit managers have become an indispensable—and controversial—part of the U.S. Healthcare system. As policymakers grapple with how to rein in their power without disrupting access to medications, one thing is clear: the status quo is unsustainable. For patients, the key is staying informed about how PBMs shape your drug benefits—and pushing for reforms that prioritize transparency and fairness over hidden profits.
With debates heating up in 2026, the next few years will determine whether PBMs evolve into more accountable partners in healthcare—or remain the shadowy middlemen driving up the cost of medicine.